# NNNN (Anbio Biotechnology) - SEC EDGAR Financial Statements

> Anbio Biotechnology reported $8.65M in revenue and net income of $6.40M for the fiscal year ended December 31, 2025 (up 5.6% year over year), with a 87.2% gross margin and a 66.7% operating margin.

- Canonical: https://convexityos.com/fundamentals/NNNN
- Markdown: https://convexityos.com/fundamentals/NNNN.md
- SEC CIK: 0001982708
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:46 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001982708&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $8.65M | +5.6% YoY |
| Operating Income | FY 2025 | $5.77M | 66.7% margin |
| Net Income | FY 2025 | $6.40M | 74.1% net margin |
| Diluted EPS | FY 2025 | $0.15 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $11.90M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of Revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| **Gross Profit** | $7.54M | $5.89M | $3.36M | $12.56M |
| Research & Development | $201K | $454K | $135K | $200K |
| Selling, General & Admin | $1.57M | $3.44M | $1.27M | $2.17M |
| Total Operating Expenses | $1.78M | $3.89M | $1.40M | $2.37M |
| **Operating Income** | $5.77M | $2.00M | $1.96M | $10.20M |
| Interest Income | $142K | $338K | $165K | $42K |
| Interest Expense | -- | -- | -- | $8.0K |
| Income Before Tax | $6.40M | $2.37M | $2.25M | $10.01M |
| Income Tax Expense | $0 | $0 | $0 | -- |
| **Net Income** | $6.40M | $2.37M | $2.25M | $10.01M |
| Basic EPS | $0.15 | $0.06 | $0.10 | $100,112.00 |
| **Diluted EPS** | $0.15 | $0.06 | $0.10 | $100,112.00 |
| Basic Shares Outstanding | 43.7M | 42.3M | 21.4M | 100 |
| Diluted Shares Outstanding | 43.7M | 42.3M | 21.4M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.77M | $11.76M | $9.69M |
| Short-Term Investments | $4.13M | $0 | -- |
| **Cash & Short-Term Investments** | $11.90M | $11.76M | $9.69M |
| Accounts Receivable, Net | $3.66M | $1.06M | $1.88M |
| Other Current Assets | $14.08M | $5.68M | -- |
| **Total Current Assets** | $30.24M | $18.53M | $15.75M |
| **Total Non-Current Assets** | $0 | $387K | $62K |
| **Total Assets** | $30.24M | $18.92M | $15.81M |
| Accounts Payable | $0 | $1.63M | $827K |
| Other Current Liabilities | $88K | $105K | $166K |
| **Total Current Liabilities** | $88K | $1.73M | $993K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 |
| **Total Liabilities** | $88K | $1.73M | $993K |
| Retained Earnings | $23.58M | $17.17M | $14.80M |
| **Total Stockholders' Equity** | $30.16M | $17.19M | $14.82M |
| Total Equity | $30.16M | $17.19M | $14.82M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.77M | $11.76M | $9.69M |
| Short-Term Investments | $4.13M | $0 | -- |
| **Cash & Short-Term Investments** | $11.90M | $11.76M | $9.69M |
| Accounts Receivable, Net | $3.66M | $1.06M | $1.88M |
| Other Current Assets | $14.08M | $5.68M | -- |
| **Total Current Assets** | $30.24M | $18.53M | $15.75M |
| **Total Non-Current Assets** | $0 | $387K | $62K |
| **Total Assets** | $30.24M | $18.92M | $15.81M |
| Accounts Payable | $0 | $1.63M | $827K |
| Other Current Liabilities | $88K | $105K | $166K |
| **Total Current Liabilities** | $88K | $1.73M | $993K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 |
| **Total Liabilities** | $88K | $1.73M | $993K |
| Retained Earnings | $23.58M | $17.17M | $14.80M |
| **Total Stockholders' Equity** | $30.16M | $17.19M | $14.82M |
| Total Equity | $30.16M | $17.19M | $14.82M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | $6.40M | $2.37M | $2.25M | $10.01M |
| Change in Receivables | -$2.59M | $820K | -$1.88M | $718K |
| Change in Inventory | -- | -- | $354K | -$354K |
| Change in Payables | -$1.63M | $798K | -$581K | -$482K |
| **Operating Cash Flow** | -$6.74M | $2.08M | $898K | $4.45M |
| Purchases of Investments | -- | -$35.47M | -$18.54M | -$16.09M |
| **Investing Cash Flow** | -$4.20M | $337K | $1.73M | -$1.53M |
| Common Stock Issued | $7.23M | $0 | $0 | -- |
| **Financing Cash Flow** | $6.95M | -$345K | -$43K | -- |
| **Net Change in Cash** | -$3.99M | $2.07M | $2.59M | $2.92M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Gross Margin** | 87.2% | 71.9% | 50.1% | 53.4% |
| **Operating Margin** | 66.7% | 24.4% | 29.2% | 43.3% |
| **Net Profit Margin** | 74.1% | 29.0% | 33.6% | 42.5% |
| Return on Equity (ROE) | 21.2% | 13.8% | 15.2% | -- |
| Return on Assets (ROA) | 21.2% | 12.5% | 14.3% | -- |
| Current Ratio | 344.31x | 10.71x | 15.86x | -- |
| Quick Ratio | 177.12x | 7.41x | 11.65x | -- |
| **Revenue Growth (YoY)** | +5.6% | +21.9% | -71.5% | -- |
| Gross Profit Growth (YoY) | +28.2% | +75.1% | -73.2% | -- |
| Operating Income Growth (YoY) | +189.1% | +1.8% | -80.8% | -- |
| **Net Income Growth (YoY)** | +169.9% | +5.3% | -77.5% | -- |
| EPS Growth (YoY) | +162.5% | -46.7% | -100.0% | -- |
| Operating Cash Flow Growth (YoY) | -423.9% | +131.6% | -79.8% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
